Integrated efficacy and safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC). (February 2017) - Oaknin, A.; Oza, A.; Tinker, A.V.; Ray-Coquard, I.; Coleman, R.; O'Malley, D.; Shapira-Frommer, R.; Leary, A.; Chen, L.M.; Provencher, D.; Ma, L.; Brenton, J.; et al.